1. Introduction {#sec1}
===============

Composite lymphoma (CL) is defined by two or more morphologically and immunophenotypically distinct lymphomas observed within the same anatomic site \[[@B1]\]. Only 6 cases of composite FL and MCL lymphoma have been reported to date ([Table 1](#tab1){ref-type="table"}) \[[@B2]--[@B7]\], and FL with coexistent MCLIS cases have only been described in 6 patients ([Table 2](#tab2){ref-type="table"}) \[[@B5]--[@B9]\]. The FL component typically appears to be low grade, harbors the t(14; 18) translocation, and stains positive for Bcl-2 on immunohistochemistry (IHC). The MCL component, however, displays a diffuse or*in situ* mantle-zone growth pattern, harbors the t(11; 14) translocation, and expresses CCND1 \[[@B10], [@B11]\]. The incidence of CL ranges from 1--4.7% of total lymphomas and has no gender or ethnic predilection. Here, we add one more case to the rare collection of FL with "*in situ*" MCL, where such findings are often incidental and associated with indolent clinical course.

2. Case Presentation {#sec2}
====================

A 65-year-old male with a history of gastric bypass surgery and left inguinal hernia repair presented with left groin swelling for two months without any other associated symptoms. He initially presented with an enlarged, palpable, nontender left inguinal lymph node measuring 1 × 1.5 cm. Initial laboratory results, including complete blood count, complete metabolic panel, lactate dehydrogenase, and beta-2-microglobulin, were normal. Computed tomography scan detected multiple lymph nodes in the mesenteric, aortocaval, and right common iliac lymph nodes measuring up to 13 mm in diameter. At the time of surgical evaluation, the inguinal lymph node had regressed and was difficult to pinpoint by physical exam. He, therefore, underwent excisional biopsy of a mesenteric lymph node visible on the CT scan ([Figure 1](#fig1){ref-type="fig"}). The follicular center site stained positive for PAX5, CD20, CD10, Bcl-2, and B-cell lymphoma 6 (Bcl-6), indicating follicular lymphoma. However, CCND1 unexpectedly highlighted CD5 positive mantle zone cells in neoplastic follicles, which suggested a MCLIS ([Figure 2](#fig2){ref-type="fig"}) component. FISH analysis demonstrated 35% of t(11; 14) and 65% of t(14; 18) in tested nuclei that are mutually exclusive. Further workups including bone marrow biopsy and aspirate were unremarkable. Colonoscopy with random biopsies was negative with no evidence of malignancy although esophagogastroduodenoscopy was not feasible due to his recent gastric bypass surgery. The patient has been followed up for 2 years since initial diagnosis of composite lymphoma and is currently under active clinical surveillance without any signs of disease progression.

3. Discussion {#sec3}
=============

FL is one of the common non-Hodgkin lymphomas with an estimated incidence of 3.18 cases per 100,000 people in the USA \[[@B12]\]. FL can present with asymptomatic lymphadenopathy and bone marrow involvement; however, extranodal involvement is relatively uncommon \[[@B13]\]. FL is the prototype for indolent lymphomas and has a median overall survival of greater than 10 years with current treatment paradigms \[[@B13]\]. FL arises from follicular germinal centers within lymph nodes, when naïve B-cells undergo somatic hypermutation (SHM) in the VH region of the immunoglobulin genes during antigen stimulation. Normally, B-cells with lower affinity to antigen undergo apoptosis (negative selection); however, the FL precursors with t(14; 18) (q32; q21) rearrangement are able to survive through negative selection due to constitutive Bcl-2 overexpression. During SHM, additional point mutations, deletions, and duplications are introduced in the DNA sequence of VH region that can contribute to pathogenesis of FL \[[@B14]\].

MCL is an aggressive and relatively rare lymphoma with an annual incidence of approximately 4--8 cases per million in the USA \[[@B15], [@B16]\]. 70% of MCL cases present with advanced disease characterized by splenomegaly, nodal, and/or extranodal involvements \[[@B17], [@B18]\]. A small subset of patients may follow an indolent clinical course, although clinical progression warrants early therapeutic intervention \[[@B18], [@B19]\]. Morphologically, five cytological variants of MCL have been recognized: classic, small cell, marginal zone-like, pleomorphic, and blastoid. The t(11; 14) (q13; 32) chromosomal rearrangement is the hallmark of MCL, and it results in overexpression of protooncogene, CCND1 \[[@B20]\].

*In situ* lymphomas are recognized in the WHO classification of both MCL and FL. They are usually incidental findings in reactive-appearing lymph nodes \[[@B21]\].*In situ* mantle cell lymphoma (MCLIS) is characterized by CCND1 positive MCL-like cells restricted to the mantle zone of hyperplastic follicles in reactive lymphoid tissues of healthy individuals \[[@B22]\]. MCLIS is extremely rare with only 22 cases reported to date. It has a heterogeneous clinical presentation with 6 cases demonstrating extranodal disease (i.e., lacrimal glands, nasopharynx, oropharynx, and gastrointestinal tract), 1 case with splenic involvement, and bone marrow involvement in 26% of reported cases ([Table 3](#tab3){ref-type="table"}) \[[@B8], [@B22]--[@B28]\]. The diagnosis of MCLIS is often made incidentally from biopsies performed during lymphoma workup. Morphologically, the architecture of the lymphoid tissue remains intact and reactive follicles are mainly distributed in the cortical areas. The mantle zones of these follicles are preserved and CCND1 positive cells are often restricted to mantle zones \[[@B22]\].

Most of MCLIS cells can be divided into two groups: CD5-negative and CD5-positive MCLIS. CD5-negative MCLIS can be typically seen in younger patients, where it often presents with nodal involvement and requires no treatment in most cases. On the other hand, CD5-positive MCLIS is associated with older age, extranodal involvement, and other lymphomas. Patients with CD5-positive MCLIS are more likely to require treatment. Interestingly, no difference in survival has been noted between these two groups \[[@B25]\].

The t(11; 14) (q13; q32) rearrangement juxtaposing the protooncogene CCND1 to the immunoglobulin heavy chain (IGH) complex is considered a pivotal event in the development of MCL. This translocation occurs within the bone marrow during pre-B stage differentiation with V (D) J recombination of the IGH variable region (IGHV) \[[@B10]\]. It is hypothesized that the naive B-cell carrying t(11; 14) colonizes the mantle zone of the lymphoid follicle, generating an*in situ* MCL lesion. Two distinct populations of MCLIS tumors have been recently described. SOX11-positive MCLIS tumors reside in the mantle zone of lymphoid follicles, are genetically unstable, and undergo limited IGHV somatic mutations. Alternatively, SOX11-negative MCLIS tumors are genetically stable and arise from naïve B-cells harboring t(11; 14) which enter the germinal center and undergo*IGHV*somatic hypermutations. Carvajal-Cuencia et al. found SOX11 expression in 44% of 16 cases with MCLIS and hypothesized that MCLIS may represent an early step in MCL lymphomagenesis \[[@B22]\]. One would presuppose that SOX-positive MCLIS and FL are clonally unrelated and mutually exclusive. However, previous studies show that 15--40% of MCLs carry IGHV hypermutations with a strong bias in the IGHV gene repertoire \[[@B29]\]. Collectively, these results suggest that both lymphomas may originate from the same preneoplastic clone. Unfortunately, depletion of material from confirmatory pathological studies did not permit PCR evaluation for clonality in our patient.

No guidelines have been established for the staging and management of MCLIS. The majority of patients with MCLIS will not develop overt MCL. Therefore, they can be followed up for long periods without treatment \[[@B22]\]. Tumor surveillance with imaging only in the presence of disease-related symptoms or organ involvement appears reasonable. MLCIS must be distinguished from mantle cell lymphoma with a mantle zone pattern and overt mantle cell lymphoma because their treatment approaches vary. Accordingly, staging workup to exclude other sites of involvement or rule out the coexistence of an overt lymphoma is recommended. When FL and MCLIS are reported simultaneously, the dominant lymphoma should be treated when patient requires treatment \[[@B30]\]. Our patient does not meet any indications for treatment, and he has been under active clinical surveillance for 2 years without any signs of disease progression. If there is any evidence of disease progression, we plan to repeat complete staging work-up including a bone marrow and lymph node biopsy with PCR analysis.

4. Conclusion {#sec4}
=============

The significance of MCLIS still remains obscure. At this moment, it is unknown whether MCLIS represents true precursor lesions that will progress to an overt lymphoma or are incidental findings with a low chance of progression. Composite lymphoma with FL and MCLIS can pose diagnostic and therapeutic challenges. However, with new advances in molecular pathology and lymphoma genomics, we have more opportunities to investigate these rare diseases and gain novel insights into their biology in order to benefit the management of affected patients.
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![H & E and immunohistochemical staining of follicular components. Hematoxylin and eosin stained sections showed numerous neoplastic follicles occupying almost the entire lymph node, effacing the normal nodal architecture extending from the cortex to the hilum, and invading beyond the capsule ((a) 4x). The neoplastic follicles consist of small centrocytes with ovoid shape, small angulated nuclei, clumped chromatin, and inconspicuous or absent nucleoli. Rare intermixed centroblasts are seen ((b) 20x and (c) 40 xs). Immunohistochemical staining revealed the germinal center cells expressing the pan B-cell marker CD20 ((d) 10x) in addition to germinal center-associated markers CD10 ((e) 10x), BCL-6 ((f) 10x), and BCL-2 ((g) 10x). The collective histologic and immunophenotype findings indicated a follicular lymphoma, grade 1 of 3.](CRIHEM2014-145129.001){#fig1}

![Immunohistochemical staining of*in situ* mantle cell lymphoma components. Cyclin D1 immunohistochemistry revealed a peripheral rim of positive cells within the mantle zones of the majority of the neoplastic secondary follicles ((a) 4x and (b) 20x). These cells appeared to show dim coexpression of CD5 ((c) 20x).](CRIHEM2014-145129.002){#fig2}

###### 

MCL and FL composite lymphomas.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case number   Age    Involvement        Immunohistochemistry staining                                           Treatment                              Follow-up                                                                                                                        Ref
  ------------- ------ ------------------ --------------------------------------------------------------------- ---------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- -----------
  1             66 F   Waldeyer ring\     MCL: CD5+, CD20+, IgD+, cyclinD1+, Bcl-2+, CD3−\                      Corticosteroid                           PET scan every 3--6 months                                                                                                       \[[@B2]\]
                       Tonsil\            FL: CD2+, CD10+, Bcl-2+, Bcl-6+, CD5−                                                                                                                                                                                                           
                       Pharyngeal wall\                                                                                                                                                                                                                                                   
                       Lingual tonsil\                                                                                                                                                                                                                                                    
                       Nasal cavity                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                          

  2             M      Ocular adnexa      NA                                                                    NA                                       Poor prognosis mentioned                                                                                                         \[[@B3]\]

                                                                                                                                                                                                                                                                                          

  3             84 F   Spleen             FL: CD20+, CD23+, Bcl-6+, CD5−, CD43−, Bcl-2−\                        Splenectomy\                             9 months after splenectomy, CT scan showed intra-abdominal lymphadenopathy and patient died from unknown cause 13 months later   \[[@B4]\]
                                          MCL: cyclinD1+, CD5−                                                  Patient refused additional treatment                                                                                                                                      

                                                                                                                                                                                                                                                                                          

  4             70 F   Cervical LN\       CD20+, CD3−, cyclinD1−\                                               No chemotherapy                          CT of chest and abdomen showed no evidence of lymphadenopathy or hepatosplenomegaly                                              \[[@B5]\]
                       Inguinal LN        50% of B-cell expressed CD5 (MCL)\                                                                                                                                                                                                              
                                          30% of B-cell expressed CD10 (FL)                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                          

  5             65 M   Inguinal LN        FL: CD20+, CD79a+, CD10+, Bcl-2+, CD5−, CD230, cyclinD1−, p27+\       Splenectomy                              MCL caused disease progression into spleen. One year after splenectomy, it achieved stable disease                               \[[@B6]\]
                                          MCL: CD20+, CD79a+, CD5+, CD10−, CD23−, cyclinD1+, p27−\                                                                                                                                                                                        
                                          Interfollicular areas mostly CD5+ showing distinct cylinD1 staining                                                                                                                                                                             

                                                                                                                                                                                                                                                                                          

  6             58 F   Mesenteric LN\     MCL: CD5+, CD20+, CD43+\                                              22 cycles of chemotherapy over 2 years   Complete remission                                                                                                               \[[@B7]\]
                       Small bowel        FL: CD10+, CD20+, p27+                                                                                                                                                                                                                          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

MCL *in situ* with FL.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case number   Histology                Immunohistochemistry\                       FISH/southern blot/PCR   Tissue microdissection   Molecular technique to determine clonal relationships   Results interpretation   Ref
                                         flow cytometry                                                                                                                                                                 
  ------------- ------------------------ ------------------------------------------- ------------------------ ------------------------ ------------------------------------------------------- ------------------------ -----------
  1             MCL: *In situ* \         *In situ* MCL: CD5−; cyclin D1+; CD23−\     NA                       Not done                 Not done                                                Not known                \[[@B5]\]
                FL: LG/G1                FL: CD10+; BCL2+                                                                                                                                                               

                                                                                                                                                                                                                        

  2             MCL: *In situ* \         *In situ* MCL: CD5+; cyclin D1+; CD23−\     t(11; 14) +\             Performed                IgH PCR FR1 FR3 JH                                      Clonally related         \[[@B6]\]
                FL: LG/G1                FL: CD10+; BCL2+                            t(14; 18) +                                                                                                                        

                                                                                                                                                                                                                        

  3             MCL: *In situ* \         *In situ* MCL: CD5−; cyclin D1+; CD23−\     t(11; 14) +\             Performed                IgH PCR FR2 D1--6 IgL PCR Vk/Kde                        Clonally related         \[[@B7]\]
                FL: LG/G1-2, *in situ*   FL: CD10+; BCL2−\                           t(14; 18)+                                                                                                                         
                                         *In situ* FL: CD10+; BCL2+                                                                                                                                                     

                                                                                                                                                                                                                        

  4             MCL: *In situ* \         *In situ* MCL: CD5−; cyclin D1+; CD23−\     NA                       Not done                 Not Done                                                Not known                \[[@B8]\]
                FL: Stage 4B             FL: CD10+; BCL2+                                                                                                                                                               

                                                                                                                                                                                                                        

  5             MCL: *In situ* \         *In situ* MCL: CD5+; cyclin D1−; CD23−\     t(14; 18)(q32; q21) +\   Performed                PCR for IgH                                             Clonally related         \[[@B9]\]
                FL: NA                   FL: CD10+; BCL2+                            t(11; 14)(q13; 32) +                                                                                                               

                                                                                                                                                                                                                        

  6             MCL: *In situ* \         *In situ* MCL: CD5+; cyclin D1+; CD23 NA\   t(11; 14) +\             Performed                PCR for IgH                                             Clonally related         \[[@B9]\]
                FL: NA                   FL: CD10+; BCL2+                            t(14; 18) +                                                                                                                        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Clinical features, follow-up, and management in *in situ* MCL lesions.

  Case number   Age    Site of biopsy               Management             Follow-up    Status                         CD5          Concurrent malignancy      Ref
  ------------- ------ ---------------------------- ---------------------- ------------ ------------------------------ ------------ -------------------------- ------------
  1             70 M   Cervical lymph node          W&W                    4 years      Overt MCL                      −                                       \[[@B8]\]
  2             65 F   LN                           Chemotherapy           0.5 years    AND                            −                                       \[[@B22]\]
  3             65 M   Appendix                     W&W                    4 years      Overt MCL                      \+                                      \[[@B22]\]
  4             66 M   Pelvic LN                    W&W                    4 years      Overt MCL                      \+           Prostate cancer            \[[@B22]\]
  5             68 M   LN, mediastinal              W&W                    1 year       AWD                            Not tested                              \[[@B22]\]
  6             82 M   Oropharynx                   W&W                    3 years      AWD                            \+           CLL/SLL                    \[[@B22]\]
  7             82 M   Lymph node                   Chemotherapy           1.5 years    AND                            \+           CLL/SLL                    \[[@B22]\]
  8             80 M   Inguinal LN                  Chemotherapy           N/A          N/A                            \+           CLL/SLL                    \[[@B22]\]
  9             42 F   Cervical lymph node          W&W                    1 year       Alive with no disease (AND)    −            Breast cancer              \[[@B22]\]
  10            78 F   Lacrimal gland               Not available (NA)     NA           NA                             \+           NA                         \[[@B22]\]
  11            42 M   Supraclavicular LN           Radiotherapy           1.7 years    AND                            −            Castleman disease          \[[@B22]\]
  12            58 M   Intestine                    Chemotherapy           1.4 years    AND                            \+           none                       \[[@B22]\]
  13            42 F   LN, axillary/inguinal, GIT   Chemotherapy           6 years      AND                            \+                                      \[[@B23]\]
  14            70 F   LN, submandibular            W&W                    12 years     AWD in Peripheral blood (PB)   \+           Nonspecific granulomas     \[[@B24]\]
  15            59 M   Cervical lymph node          W&W                    5 years      AND                            −            Papillary thyroid cancer   \[[@B25]\]
  16            80 M   Cervical LN                  Chemotherapy           1.5 years    Died                           \+           FL                         \[[@B25]\]
  17            65 F   Intramammary LN              Chemotherapy           5 years      AND                            \+           FL                         \[[@B25]\]
  18            65 M   Appendix                     W&W                    4 years      MCL                            \+           NA                         \[[@B25]\]
  19            68 M   Mediastinal LN               W&W                    1 year       AND                            NA           ---                        \[[@B25]\]
  20            41 F   Inguinal lymph node (LN)     Watch and Wait (W&W)   19.5 years   Alive with disease (AWD)       −            none                       \[[@B26]\]
  21            72 F   Cervical lymph node          Radiotherapy           2 years      AND                            \+           Breast cancer              \[[@B27]\]
  22            34 M   Left supraclavicular LN      Chemotherapy           1 month      Died                           \+           FL                         \[[@B28]\]

W&W: watch and wait.

AND: alive with no disease.

AWD: alive with disease.

NA: nonavailable.

CLL: chronic lymphocytic leukemia.

SLL: small lymphocytic lymphoma.

LN: lymph node.

GIT: gastrointestinal tract.
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